A5000049294- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Chronic Lymphocytic Leukemia Research
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- PARP inhibition in cancer therapy
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Mechanisms of cancer metastasis
- Computational Drug Discovery Methods
- Chromatin Remodeling and Cancer
- Cardiac Arrhythmias and Treatments
- Breast Cancer Treatment Studies
- Molecular Biology Techniques and Applications
- Single-cell and spatial transcriptomics
- Cardiovascular Syncope and Autonomic Disorders
- Cancer Mechanisms and Therapy
- Estrogen and related hormone effects
- Cancer Cells and Metastasis
- Neuroblastoma Research and Treatments
- Protein Degradation and Inhibitors
- Congenital Heart Disease Studies
Instituto de Investigación Biomédica de Málaga
2020-2025
Centro de Investigación Biomédica en Red de Cáncer
2022-2025
Centre for Biomedical Network Research on Rare Diseases
2023-2025
Hospital Clínico Universitario Virgen de la Victoria
2013-2024
Roche (Spain)
2022-2024
Instituto de Salud Carlos III
2023-2024
Vall d'Hebron Hospital Universitari
2017-2024
Royal Marsden NHS Foundation Trust
2020-2024
GEICAM – Spanish Breast Cancer Group
2023
Institute of Cancer Research
2019-2023
•Validated and sensitive ctDNA assays can be used to genotype advanced cancers select patients for targeted therapies.•Initial genotyping with should considered when rapid results are needed, tissue is unavailable.•ctDNA assay limited by false-negative results, lower sensitivity fusion events copy number changes.•Use of detect molecular residual disease not recommended, due lack evidence its clinical utility. Circulating tumour DNA (ctDNA) conducted on plasma rapidly developing a strong base...
Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is prospective cohort study of COVID-19 immunity patients with cancer. Here we evaluated 585 following administration two doses BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after were 85% and 59% solid hematological malignancies, respectively. A lower proportion had detectable titers neutralizing antibodies (NAbT) against severe acute...
In this study, our objective was to determine whether a perioperative hemodynamic protocol based on noninvasive cardiac output monitoring decreases the incidence of postoperative complications and hospital length stay in major abdominal surgery patients requiring intensive care unit admission. Secondary objectives were time peristalsis recovery wound infection, anastomotic leaks, mortality.A randomized clinical trial conducted 6 tertiary hospitals. One hundred forty-two adult scheduled for...
Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast evolves with time and under selective pressure treatment, potential acquire mutations resistance treatment disease progression. To identify potentially targetable in advanced cancer, we performed prospective characterization a cohort patients ABC.Biopsies from were sequenced 41 genes targeted panel ABC Biopsy (ABC-Bio) study. Blood samples collected at progression for...
Abstract Purpose: In hormone receptor–positive (HR+)/HER2− metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and discover therapeutic targets reverse this resistance. Non-luminal subtype high levels of CCNE1 are candidate biomarkers in setting, but further validation needed. Experimental Design: We performed mRNA gene expression profiling correlation with progression-free survival (PFS) on 455 tumor...
Abstract Background The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts personalized clinical management and the development of innovative strategies. Tumor-infiltrating Natural Killer (TI-NK) cells can predict efficacy HER2-targeted independently from clinicopathological factors primary HER2-positive breast cancer patients. Understanding mechanism/s underlying this association would contribute optimizing patient stratification provide rationale for...
PURPOSE Data from population-based studies have shown an increased incidence of certain types neoplasms in patients younger than 50 years (early-onset cancer [EOC]); however, little information is derived other real-world data sources. In a nonpopulation registry, we analyzed changes the several successive generations. METHODS This cross-sectional study included all with diagnosis registered one university hospital Málaga, Spain, between 1998 and 2021, 18 were analyzed. For each neoplasm,...
Deep brain stimulation (DBS) of the posterior hypothalamus has been found to be effective in treatment refractory chronic cluster headache (CCH).We report long-term outcomes five patients with CCH on whom a modified target approximately 3 mm radius, which included posterolateral hypothalamus, fasciculus mammillotegmentalis, mammillothalamicus and medialis telencephali, was performed. The stereotaxic coordinates were 4 from third ventricle wall, 2 behind mid-intercommissural point 5 under...
Prognostic and predictive biomarkers to cyclin-dependent kinases 4 6 inhibitors are lacking. Circulating tumor DNA (ctDNA) can be used profile these patients dynamic changes in ctDNA could an early predictor of treatment efficacy. Here, we conducted plasma profiling from the PEARL trial comparing palbociclib+fulvestrant versus capecitabine investigate associations between baseline genomic landscape on-treatment dynamics with efficacy.Correlative blood samples were collected at [cycle 1-day 1...
Analysis of circulating tumor DNA (ctDNA) is increasingly used for clinical decision-making in oncology. However, ctDNA could represent ≤ 0.1 % cell-free early-stage tumors and its detection requires high-sensitive techniques such as digital PCR (dPCR).
Raczynski y Muñoz (2007) hicieron un recorrido crítico de la reforma educacional chilena, sus logros desafíos pendientes, desde perspectiva efectividad el mejoramiento escolar. El artículo concluía que no había incidido casi en las prácticas trabajo asentadas escuelas aula desafío política educativa chilena era combinar medidas decisiones dirigidas a fortalecer lo ocurre microcosmos cada escuela, reconociendo abordando al mismo tiempo restricciones su desarrollo derivan factores...
Early breast cancer patients often experience relapse due to residual disease after treatment. Liquid biopsy is a methodology capable of detecting tumor components in blood, but low concentrations at early stages pose challenges. To detect them, next-generation sequencing has promise entails complex processes. Exploring larger blood volumes could overcome detection limitations. Herein, total 282 high-volume plasma and blood-cell samples were collected for dual ctDNA/CTCs using single...
TPS1126 Background: CDK7 enhances oncogene transcription and upregulates anti-apoptotic genes, accelerates the cell cycle via CDK phosphorylation, activates estrogen receptors (ERs) that can drive resistance to hormonal therapy in cancer. inhibition therefore represents a potential anticancer strategy Samuraciclib (CT7001) is small molecule, ATP competitive, selective oral inhibitor of inhibits these key effects CDK7. had favorable safety profile showed clinical activity when combined with...
Background: Double blockade with pertuzumab and trastuzumab combined chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that response rates differ among intrinsic subtypes of The aim this study to determine if these results are valid in real-world patients. Methods: A total 259 patients treated eight Spanish hospitals were included divided into two cohorts: Cohort (132 patients) received plus (NAC), B NAC (122...
Our objective was to determine the prevalence and characteristics of lung cancer (LC) in HIV patients compare them with LC from general population. All diagnosed at three hospitals Malaga (southern Spain) who developed during January 1989-June 2012 were reviewed. They compared a sample taken Pneumology Oncology Department Hospital Virgen de le Victoria (Malaga) same period. Of 4721 (83% men) followed-up study period, 61 (1.29%) LC: 82% men, mean age 48 years, all except two smokers, 47.5%...
Breast cancer (BC) is the most prevalent in women. While usually detected when localized, invasive procedures are still required for diagnosis. Herein, we developed a novel ultrasensitive pipeline to detect circulating tumor DNA (ctDNA) series of 75 plasma samples from localized BC patients prior any medical intervention. We first performed tumor-informed analysis correlate mutations found tissue and plasma. Disregarding data next, an approach observed mutation concordance between 29.50%...
RESUMENEl dolor es un síntoma de alta prevalencia en los pacientes con cáncer y deteriora forma importante su calidad vida.Con las medidas enunciadas por la OMS 1986, que divide tres escalones ascendentes distintas opciones terapéuticas disponemos, el puede ser controlado alto porcentaje casos.Aquellos difíciles controlar estas medidas, se pueden beneficiar aplicación técnicas neuromodulación expertos tratamiento del crónico.El correcto manejo distintos fármacos (AINES, opiáceos...
1051 Background: PI3K and CDK4/6 inhibitors synergise in ER+ve –ve PIK3CA-mt breast cancer (BC) models. Escalation phase of this study set recommended 2 dose (RP2D) at P 125mg on a 3/1 scheme plus T 2mg daily ( Lim, ASCO 2017). Here we present the results expansion cohorts for BC patients (pts). Methods: The primary objective was to assess confirmed response rate (ORR) + FUL triplet pts with measurable HER2-ve advanced BC, up two prior lines chemotherapy disease. PIK3CA mutation assessed...
3087 Background: Oncogenic hyperactivation of the PI3K pathway is common in multiple cancers, with preclinical data showing that CDK4/6 inhibitors sensitise PIK3CA mutant cancers to inhibitors. We report activity P+T solid tumors activation, along PD biomarker analysis. Methods: previously reported dose escalation phase identifying 125mg P given 3-weeks-on, 1-week-off combination T 2mg as recommended 2 (R2PD, Lim, ASCO 2017). results confirmed activating mutations (mts) pathway, from and...